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Objectives. The purpose of this study was to assess the effects of
enalapril and nitrendipine on the cardiac sympathetic nervous
system.
Background. Angiotensin-converting enzyme inhibitors and
long-acting calcium channel blockers have been widely used in the
treatment of cardiovascular diseases, in some of which sympa-
thetic overactivity plays a major role in the pathophysiology and
prognosis. However, little information is available on the effects of
these drugs on the cardiac sympathetic nervous system.
Methods. 123I-metaiodobenzylguanidine (MIBG) cardiac imag-
ing was performed before and 3 months after drug administration
in 46 patients with mild essential hypertension. Twenty-two
patients were treated with 5 to 10 mg of enalapril once a day, and
the other 24 with 5 to 10 mg of nitrendipine once a day. For
comparison, 20 normotensive subjects were also studied.
Results. There were no significant differences between the basal
characteristics in the 2 hypertensive groups. In both hypertensive
groups, both systolic and diastolic blood pressures were signifi-
cantly reduced to similar levels after the 3-month drug treatment.
Before the drug treatment, the 2 hypertensive groups had a
significantly higher washout rate and lower MIBG uptake than
the normotensive subjects. The heart-to-mediastinum ratio signif-
icantly increased (p < 0.0001), with decreased (p < 0.002)
washout rate after drug treatment in the enalapril group, but with
no significant changes in the nitrendipine group.
Conclusion. Enalapril could suppress cardiac sympathetic ac-
tivity and nitrendipine had no effect on it. The knowledge of
antihypertensive drugs on the cardiac sympathetic nervous system
appears to be helpful in selecting appropriate treatment in
cardiovascular diseases.
(J Am Coll Cardiol 1998;32:438–43)
©1998 by the American College of Cardiology
Sympathetic overactivity is proposed as a pathophysiologic
finding in several cardiovascular diseases (1–6). This is sup-
ported, in part, by the widespread use of beta-blocking agents
to treat these cardiovascular diseases effectively (7–9). Re-
cently, numerous investigators (10–12) have recommended the
use of angiotensin-converting enzyme (ACE) inhibitor in
cardiovascular diseases because of its beneficial effects on the
cardiovascular system, among them a proposed effect on the
sympathetic nervous system (13). On the other hand, the issue
that the use of short-acting calcium channel blockers is asso-
ciated with increased risk of acute myocardial infarction and
mortality (14) or does not reduce the incidence of cardiac
events (15) has cast doubt on the usefulness of long-acting
calcium channel blockers in cardiovascular diseases. Neuro-
hormonal activation is considered to be an important variable
participating in the unexpected results obtained with short-
acting calcium channel blockers (16). To date, no large-scale
long-term clinical trials of long-acting calcium channel block-
ers in patients with cardiovascular diseases have been reported
other than one recent clinical trial in patients with hyperten-
sion (17). That study revealed that nitrendipine reduced the
overall incidence of cardiac events in elderly hypertensives.
The effect of nitrendipine on the sympathetic nervous system,
however, remains unknown, despite the known association
between sympathetic activation and heart disease. Cardiac
sympathetic activity seems to be particularly important because
sympathetic outflow is not necessarily uniformly distributed
across the organs (18) and the cardiac sympathetic nervous
system is associated with prognosis of heart failure (19,20).
Although it was previously difficult to assess cardiac sym-
pathetic nerve activity in vivo, 123I metaiodobenzylguanidine
(MIBG), an analog of guanidine that shares the same neuronal
transport and storage mechanisms with norepinephrine, is now
used to evaluate the sympathetic activity and innervation of the
left ventricle (20–27), where most severe forms of heart
disease originate.
Using MIBG imaging in patients with essential hyperten-
sion, we compared the effects on the cardiac sympathetic
nervous function of enalapril, an ACE inhibitor, with those of
nitrendipine, a long-acting calcium channel blocker.
Methods
Patients. We selected 46 male patients with mild essential
hypertension over 39 years of age (range 40 to 69) who were
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referred to cardiac catheterization because of chest pain
and/or electrocardiographic abnormalities that revealed nor-
mal coronary arteries without spasm and normal cardiac
function. According to the Guidelines Sub-committee of the
WHO/ISH Mild Hypertension Liaison Committee (28), mild
hypertension was defined as persistent resting levels of dia-
stolic blood pressure between 90 and 105 mm Hg and/or
systolic blood pressure between 140 and 180 mm Hg. All
hypertensive patients in the present study met these criteria.
They were allocated randomly into 2 groups: 22 of the men
received oral enalapril (5 to 10 mg) once a day and the other
24 men received oral nitrendipine (5 to 10 mg) once a day. We
also selected 20 normotensive male subjects (122 6 16 mm
Hg/76 6 8 mm Hg) with normal coronary and left ventricular
function as a control group. None of the study patients had
diabetes mellitus or any other disease affecting the autonomic
nervous system. They underwent MIBG imaging within one
month after cardiac catheterization and also repeat MIBG
imaging 3 months after the start of the drug treatment. All
hypertensive patients were newly diagnosed and had not
received any antihypertensive therapy except for diet therapy
before first MIBG imaging. Informed consent was obtained
from each patient. This study protocol was approved by the
hospital’s ethics committee.
Coronary angiography. Coronary angiography with the
acetylcholine provocation test was performed by the standard
Judkins technique in all patients.
Echocardiography. Echocardiograms were recorded, with
the patient in the supine position turned 30° on his left side,
using an SSD-870 echocardiograph (Aloka Co., Ltd., Tokyo,
Japan) with a 3.5-MHz transducer. M-mode echocardiograms
were recorded under 2-dimensional guidance, and the tracing
was recorded at a paper speed of 100 mm/s. Measurements
were obtained to the nearest millimeter for at least 4 cardiac
cycles during quiet respiration, and the average values were
used for analysis. All echocardiograms were recorded with the
patient in the same position, in the same intercostal and left
ventricular area, just below the tip of the mitral leaflets. All
measurements were obtained by the same observer according
to the guidelines of the American Society of Echocardiography
(29). The parameters measured or calculated were the left
ventricular end-diastolic and end-systolic dimensions, and the
septal and posterior wall thickness in systole and diastole. In
addition, the left ventricular mass (LVM) was calculated as
follows (30): 1.05 3 p/3{[2 (left ventricular end-diastolic
dimension) 1 (septal 1 posterior wall thickness in diastole)] 3
[left ventricular end-diastolic dimension 1 (septal 1 posterior
wall thickness in diastole)]2/2} 2 (left ventricular end-diastolic
dimension)3. LVM was divided by the body surface area to
obtain the LVM index (LVMI) (g/m2). LV ejection fraction
(EF) was also calculated according to the American Society of
Echocardiography criteria by the area-length method (31).
MIBG scintigraphy. After an overnight fast, a dose of 111
MBq of commercially available MIBG (Daiichi Radioisotopes
Labs, Ltd., Tokyo, Japan) was administered intravenously. A
5-minute static acquisition was made every 15 minutes and 3
hours after injection of MIBG in the anterior view. Cardiac
images were acquired after each static acquisition, using a
three-head gamma camera (Toshiba GCA 9300A/HG, Tokyo,
Japan) equipped with parallel-hole, high-resolution collima-
tors. Energy discrimination was provided by a 15% window
centered at 159 keV. Data processing was performed on a
Toshiba GMS 5500A system.
Left ventricular MIBG activity and washout rate were
measured by using square region-of-interests placed over the
left ventricle with the peak count density and over the upper
mediastinum. The heart-to-mediastinum ratio (H/M ratio) on
the delayed image was calculated to quantify cardiac MIBG
uptake as a fraction of the mean count per pixel in the heart
divided by those in the upper mediastinum (20). The myocar-
dial washout rate was defined as the percent change in activity
from the initial to the delayed images within the left ventricle
and calculated as follows: washout rate (%) 5 (A2B)/A 3
100, where A 5 average count/pixel in the left ventricle on the
initial image and B 5 average decay-corrected count/pixel in
the same region on the delayed image. Decay correction was
performed assuming that the half-life of the radionuclide
(I-123) was 13 hours.
Hormone analysis. After the patient had rested in the
supine position for 30 minutes in a warm, quiet, darkened
room between 8:00 and 9:00 AM before MIBG imaging, his
blood pressure was measured and venous blood samples were
drawn from an indwelling catheter inserted in the median
cubital vein. Blood samples were stored at 270°C. The plasma
norepinephrine concentration was determined by a high-
performance liquid chromatography (32). This method detects
norepinephrine levels as low as 10 pg/ml. The intra- and
interassay coefficient of variation were 1.1% and 0.5%, respec-
tively.
Statistical analysis. Data are expressed as mean 6 SD.
Comparisons among 3 groups (normotensive subjects, patients
with enalapril and patients with nitrendipine) were performed
by one-way analysis of variance (ANOVA) followed by Bon-
ferroni multiple comparison test. Statistical evaluation was also
performed by ANOVA with repeated measurements, which
included the effects of enalapril and nitrendipine and compar-
isons between groups, and, if significant differences were
detected by ANOVA, the paired t test was performed on the
relevant data pair. Chi-square or Fisher’s exact test was used to
determine the significance of differences in the observed
occurrence rates. A p value less than 0.05 was considered
significant.
Abbreviations and Acronyms
ACE 5 angiotensin-converting enzyme
H/M ratio 5 heart-to-mediastinum ratio
LVM 5 left ventricular mass
LVMI 5 left ventricular mass index
MIBG 5 123I metaiodobenzylguanidine
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Results
Baseline characteristics. Baseline clinical characteristics of
the hypertensive patients and normotensive subjects are listed
in Table 1. There were no significant differences in age, body
mass index and coronary risk factors among the 3 groups, and
no difference in blood pressure levels was recognized between
the 2 hypertensive groups. In addition, echocardiographic
findings were comparable across the 3 groups.
Changes in hemodynamics and hormones. Changes in
blood pressure, heart rate and plasma norepinephrine concen-
tration before and after drug treatment are presented in Table
2. There were no significant differences in any of the parame-
ters between the 2 groups before and 3 months after drug
treatment. In both groups, both systolic and diastolic blood
pressures were significantly reduced after drug treatment,
although heart rate did not change significantly. In addition,
plasma norepinephrine concentration did not change signifi-
cantly after drug administration in either group.
Changes in scintigraphic variables after drug treatment.
Compared with the normotensive group before drug treat-
ment, the 2 hypertensive groups had significantly higher wash-
out rates (5.4 6 3.8 in normotensive subjects vs. 18.1 6 11.4 in
the enalapril group [p , 0.0001] and vs. 13.3 6 9.3 in the
nitrendipine group [p , 0.005]) and lower H/M ratio (2.22 6
0.21 vs. 1.89 6 0.34 [p , 0.0003] and vs. 2.00 6 0.27 [p , 0.01],
respectively) (Fig. 1). Figure 2 shows the scintigraphic vari-
ables before and 3 months after drug treatment in the 2
hypertensive groups. In the enalapril group, the H/M ratio
significantly increased (1.89 6 0.34 vs. 2.08 6 0.35, p , 0.0001)
after drug treatment, but there was no significant change in the
ratio in the nitrendipine group (2.00 6 0.27 vs. 2.01 6 0.26, p 5
NS). In addition, the washout rate significantly changed in the
enalapril group (18.1 6 11.4 vs. 13.9 6 11.0, p , 0.002) but not
in the nitrendipine group (13.3 6 9.3 vs. 12.3 6 9.1, p 5 NS).
Ten of the normotensive subjects underwent repeat MIBG
imaging 3 months after the first MIBG imaging. The H/M ratio
was 2.20 6 0.23 at the first and 2.16 6 0.20 at the second test
(p 5 NS), and the washout rate was 5.7 6 3.3 and 5.8 6 3.3
(p 5 NS), respectively. Correlation analysis revealed high
reproducibility of both the H/M ratio (r 5 0.93, p , 0.001) and
washout rate (r 5 0.96, p , 0.0001).
Discussion
Essential hypertension and the cardiac sympathetic ner-
vous system. The present study demonstrated that hyperten-
sive patients had lower MIBG uptake and higher washout rate
than normotensive subjects. These MIBG findings in essential
hypertension are consistent with those in cardiovascular dis-
eases with cardiac sympathetic overactivity (20,21,23,24,26).
Furthermore, recent microneurographic studies (2,3) have
demonstrated that the central sympathetic neural outflow is
augmented in essential hypertension. Likewise, activation of
the cardiac sympathetic nervous system in essential hyperten-
sion was documented using power spectral analysis (4) and
measurement of tritiated norepinephrine (1). Therefore, it is
reasonable to assume that the abnormalities of MIBG imaging
in the present study result from cardiac sympathetic overactiv-
ity in essential hypertension.
The reliability of the MIBG-imaging process for quantita-
tively assessing sympathetic nerve activity has been demon-
strated in a large number of MIBG studies. Experimentally,
Sisson et al. (22) demonstrated that movements of MIBG in
the heart largely mimic those of tritiated norepinephrine,
indicating that MIBG release from the heart reflects sympa-
thetic nerve activity. In addition, Takatu et al. (23) demon-
strated that accelerated MIBG washout in Syrian hamsters was
due to increased firing of the sympathetic nerves. Clinically,
Schofer et al. (24) demonstrated that the H/M ratio was related
to MIBG activity and norepinephrine concentration in the
human myocardium. Using a quantitative method similar to
ours, Imamura et al. (26) suggested that MIBG washout was













Age (yr) 59 6 8 61 6 8 65 6 7
Smoking 6 5 6
Hypercholesteremia 4 6 5
FH 8 8 6
Hyperuricemia 4 4 3
Body mass index (kg/m2) 23 6 2 24 6 3 24 6 2
Echocardiographic
variables
LVM (g) 141 6 17 150 6 23 154 6 23
LVMI (g/m2) 91 6 11 97 6 15 100 6 14
EF (%) 68 6 9 65 6 6 67 6 5
Values are expressed as mean 6 SD. EF 5 ejection fraction; FH-family
history of coronary artery disease; LVM-left ventricular mass; LVMI-left ven-
tricular mass index.
Table 2. Changes in Hemodynamics and Plasma
Norepinephrine Concentration
Enalapril Nitrendipine
Systolic BP (mm Hg)
Before 164 6 10 174 6 20
After 140 6 11* 140 6 15*
Diastolic BP (mm Hg)
Before 97 6 4 97 6 10
After 80 6 6* 77 6 8*
HR (beats/min)
Before 72 6 4 70 6 5
After 70 6 6 73 6 2
Norepinephrine(ng/L)
Before 299 6 134 276 6 120
After 244 6 108 269 6 99
*p , 0.001, compared with the value before drug treatment. There was no
significant difference in any variable between the 2 groups. Values are expressed
as mean 6 SD. BP-blood pressure; HR-heart rate.
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more closely associated with sympathetic activity than MIBG
uptake in heart failure, since MIBG washout is independent of
the number of neurons available, whereas the H/M ratio is not.
In addition, Morozumi et al. (25) demonstrated that the H/M
ratio and MIBG washout rate correlated with sympathetic
nerve activity, which was determined by power spectral analysis
of heart rate variability. These results corroborate our theory
that quantitative analysis of cardiac MIBG images is a reliable
method to assess cardiac sympathetic nerve activity. In consid-
ering the report by Imamura et al. (26) and the responses of
MIBG washout and uptake to atropine (27), MIBG washout
appears to be more closely associated with sympathetic nerve
activity than MIBG uptake.
Effect of enalapril on the cardiac sympathetic nervous
system. Using MIBG imaging, several investigators have dem-
onstrated that enalapril increases MIBG uptake and reduces
MIBG washout rate in heart failure, suggesting that enalapril
has a beneficial effect on the cardiac sympathetic nervous
system in heart failure (33). However, ACE inhibitors are
shown to have beneficial hemodynamic effects that reduce
norepinephrine release in heart failure. Therefore, it is unclear
whether improvement in sympathetic activity is due to the
direct influence of ACE inhibitors on the sympathetic nervous
system or to their beneficial systemic effects in patients with
heart failure. Noll et al. (34) demonstrated that captopril did
not reduce muscle sympathetic activity compared with its
resting activity, but did so when compared with placebo despite
reduction in diastolic blood pressure that appears to be
important for baroreceptor-mediated activation of the sympa-
thetic nervous system (35). In contrast, we demonstrated that
enalapril increased MIBG uptake and reduced MIBG washout
rate in essential hypertension, suggesting that enalapril sup-
presses cardiac sympathetic overactivity. However, enalapril did
not affect a global index of sympathetic activity, such as plasma
norepinephrine concentration, in patients with essential hyper-
tension. Thus, enalapril could suppress cardiac sympathetic activ-
ity without affecting plasma norepinephrine concentration despite
a significant reduction in diastolic blood pressure.
Several mechanisms contributing to the inhibition of sym-
pathetic nervous activity by ACE inhibitors have been pro-
posed. ACE inhibitors may reduce norepinephrine release by
reducing angiotensin II concentration. Angiotensin II facili-
tates norepinephrine release at presynaptic sites (36) and
stimulates sympathetic outflow by activating specific binding
sites in the brainstem (37). In addition, ACE inhibition may
lead to enhanced prostaglandin formation via accumulation of
bradykinin (38), which may inhibit norepinephrine release at
presynaptic sites (39). On the basis of an interaction between
the sympathetic nervous system and the renin-angiotensin
system, enalapril may decrease the enhanced cardiac sympa-
thetic nervous system in essential hypertension.
Calcium channel blocker and sympathetic activity. The
reflex increase in sympathetic activity induced by short-acting
dihydropyridine calcium channel blockers has been demon-
strated (16). This increase is considered to be one of the major
adverse factors of cardiovascular diseases (40). However, it
remains unknown whether this reflex increase is associated
with the short-term and with the rapid action of dihydropyri-
dine calcium channel blockers. Frohlich et al. (16) demon-
strated that long-acting nifedipine does not increase plasma
Figure 1. Comparisons of heart/mediastinum
(H/M) ratio and washout rate among 20 normo-
tensive subjects, 22 patients with essential hyper-
tension before enalapril administration, and 24
patients with essential hypertension before ni-
trendipine administration.
Figure 2. Comparison of heart/mediastinum (H/M) ratio and washout
rate before and 3 months after drug treatment in hypertensive patients
treated with enalapril and in those treated with nitrendipine.
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norepinephrine concentration but that short-acting nifedipine
does. They suggested that the duration as well as the strength
of the action of antihypertensive drugs may affect the sympa-
thetic nervous system. However, recent studies demonstrated
that long-acting dihydropyridine calcium channel blockers,
such as amlodipine and felodipine, could activate the sympa-
thetic nervous system (41,42). In contrast, we demonstrated
that nitrendipine (5 to 10 mg) did not change the cardiac
MIBG kinetics and plasma norepinephrine concentration de-
spite lowering systemic blood pressure to a degree similar to
that produced by enalapril; this suggests that nitrendipine did
not influence the cardiac sympathetic nervous system and did
not induce an increase in plasma norepinephrine concentra-
tion, probably resulting from baroreceptor-mediated activation
of the sympathetic nervous system. Thus, nitrendipine did not
affect the sympathetic nervous system, although sympathetic
activation may depend on used dosages of the drug.
Clinical implications. Among patients with heart diseases,
those with sympathetic activation have a high mortality rate
(19). Therefore, modulation of the cardiac sympathetic ner-
vous system by medication is worth considering as a treatment
for such patients. Because decreased MIBG uptake and in-
creased MIBG washout are shown to be associated with
unfavorable prognosis (20), we expect that enalapril could
improve the prognosis in such patients. In fact, enalapril has
been shown to have beneficial effects on the prognosis of
patients with heart failure (10,11) whose reported MIBG
findings (20,26) were similar to those of patients with essential
hypertension in this study. Nitrendipine, on the other hand,
does not seem to affect the cardiac sympathetic nervous
system. Regarding the question of whether this feature offers
an advantage to patients receiving long-term treatment with
nitrendipine, a recent study—the Systolic Hypertension in
Europe (SYST-EUR) Trial (17)—demonstrated that active
treatment with nitrendipine for elderly patients with isolated
systolic hypertension decreased all fatal and nonfatal cardiac
events significantly, although the effect on cardiovascular mor-
tality did not reach statistical significance. Therefore, nitren-
dipine could improve cardiovascular mortality and morbidity
in hypertensive patients. Further investigations are needed to
examine whether nitrendipine is more beneficial to patients
with essential hypertension and/or other cardiovascular dis-
eases than ACE inhibitors or beta blockers.
We were able to assess the effects of antihypertensive drugs
on the cardiac sympathetic nervous system with MIBG find-
ings. In addition, because increased cardiac sympathetic ner-
vous activity is associated with poor prognosis in heart disease
and we have found that degrees of MIBG uptake and washout
are different at each clinical stage of essential hypertension
(43), MIBG findings in essential hypertension have implica-
tions with regard to clinical information about each patient’s
condition and a risk for developing cardiovascular complica-
tions.
Conclusions. In essential hypertension, enalapril improved
MIBG kinetics, whereas nitrendipine had no effect on MIBG
kinetics, although these drugs did not affect plasma norepi-
nephrine concentration. These results suggest that enalapril
could suppress cardiac sympathetic activity, but nitrendipine
had no effect on it in essential hypertension. Consideration of
the different effects of antihypertensive drugs on the cardiac
sympathetic nervous system may be helpful in finding more
effective and beneficial treatments for patients with cardiovas-
cular disease.
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